PYXS

SEC source: 0001567619-23-000067 · doc1.xml · nonDerivative · entry 1

Feingold Jay · CIK 0001885838 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 520,542

F1 · shares: Represents restricted stock units that vest on April 13, 2023, subject to the Reporting Person's continued employment through the vesting date.

SEC source: 0001567619-23-000068 · doc1.xml · nonDerivative · entry 1

Sullivan Lara · CIK 0001769457 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,452,320

F1 · shares: Represents restricted stock units that vest on April 13, 2023, subject to the Reporting Person's continued employment through the vesting date.

SEC source: 0001567619-23-000066 · doc1.xml · nonDerivative · entry 1

Yanchik Connealy Pamela · CIK 0001796310 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 384,510

F1 · shares: Represents restricted stock units that vest on April 13, 2023, subject to the Reporting Person's continued employment through the vesting date.

SEC source: 0001140361-22-029677 · form4.xml · derivative · entry 1

HUMPHREY RACHEL · CIK 0001579781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 236,220

Underlying: Common Stock · 236,220 shares

Expires 2032-08-11

F1 · derivative.exercise_date: These stock options vest in three equal annual installments from the grant date, subject to the reporting person's continued service through the applicable vesting date.

SEC source: 0000899243-22-015542 · doc4.xml · nonDerivative · entry 1

Chin Mark · CIK 0001734389 · Former Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · ownership.nature: The securities were held directly by Arix Bioscience Holdings Limited ("Arix"). The Reporting Person is one of for members of the Investment Committee of Arix and, in such capacity, may be deemed to share voting and dispositive power over the securities held by Arix. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his respective pecuniary interests therein.

SEC source: 0001567619-22-008614 · doc1.xml · nonDerivative · entry 1

Feingold Jay · CIK 0001885838 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 466,611

F1 · shares: Represents restricted stock units ("RSUs") that vest on April 13, 2023, subject to the Reporting Person's continued employment through the vesting date.

F2 · shares: The Compensation Committee also approved a grant to the Reporting Person, effective January 3, 2023, of an additional 53,931 RSUs that vest on April 13, 2023, subject to the Reporting Person's continued employment through the grant and vesting dates.

SEC source: 0001567619-22-008613 · doc1.xml · nonDerivative · entry 1

Sullivan Lara · CIK 0001769457 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,356,636

F1 · shares: Represents restricted stock units ("RSUs") that vest on April 13, 2023, subject to the Reporting Person's continued employment through the vesting date.

F2 · shares: The Compensation Committee also approved a grant to the Reporting Person, effective January 3, 2023, of an additional 95,684 RSUs that vest on April 13, 2023, subject to the Reporting Person's continued employment through the grant and vesting dates.

F3 · shares: The Compensation Committee also approved a grant to the Reporting Person of $200,000 cash compensation that is payable in full on April 13, 2023, subject to the Reporting Person's continued employment through the payment date.

SEC source: 0001567619-22-008615 · doc1.xml · nonDerivative · entry 1

Yanchik Connealy Pamela · CIK 0001796310 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 341,017

F1 · shares: Represents restricted stock units ("RSUs") that vest on April 13, 2023, subject to the Reporting Person's continued employment through the vesting date.

F2 · shares: The Compensation Committee also approved a grant to the Reporting Person, effective January 3, 2023, of an additional 43,493 RSUs that vest on April 13, 2023, subject to the Reporting Person's continued employment through the grant and vesting dates.

SEC source: 0001140361-22-012921 · form4.xml · nonDerivative · entry 1

FLAVIN JOHN L · CIK 0001126556 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 238,441

F1 · shares: Represents restricted stock units that vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.

SEC source: 0001140361-22-012918 · form4.xml · nonDerivative · entry 1

Feingold Jay · CIK 0001885838 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 350,680

F1 · shares: Represents restricted stock units that vest over a four-year period, with 25% vesting on the first anniversary of the grant date, and the remaining 75% vesting in 12 substantially-equal quarterly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.

SEC source: 0001140361-22-012917 · form4.xml · nonDerivative · entry 1

Chin Mark · CIK 0001734389 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,831

F1 · shares: Represents restricted stock units that vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.

SEC source: 0001140361-22-012913 · form4.xml · nonDerivative · entry 1

Lewis-Hall Freda C · CIK 0001437909 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,831

F1 · shares: Represents restricted stock units that vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.

SEC source: 0001140361-22-012914 · form4.xml · nonDerivative · entry 1

Cline Darren S · CIK 0001633639 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,831

F1 · shares: Represents restricted stock units that vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.

SEC source: 0001140361-22-012916 · form4.xml · nonDerivative · entry 1

Yanchik Connealy Pamela · CIK 0001796310 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 247,524

F1 · shares: Represents restricted stock units that vest over a four-year period, with 25% vesting on the first anniversary of the grant date, and the remaining 75% vesting in 12 substantially-equal quarterly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.

SEC source: 0001140361-22-012919 · form4.xml · nonDerivative · entry 1

Civik Thomas · CIK 0001723092 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,831

F1 · shares: Represents restricted stock units that vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.

SEC source: 0001140361-22-012924 · form4.xml · nonDerivative · entry 1

Sullivan Lara · CIK 0001769457 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,041,363

F1 · shares: Represents restricted stock units that vest over a four-year period, with 25% vesting on the first anniversary of the grant date, and the remaining 75% vesting in 12 substantially-equal quarterly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.

SEC source: 0000899243-21-047525 · doc4.xml · nonDerivative · entry 1

Cline Darren S · CIK 0001633639 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.109 to $9.5561, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein

SEC source: 0000899243-21-047102 · doc4.xml · derivative · entry 1

Yanchik Connealy Pamela · CIK 0001796310 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,944

Underlying: Common Stock · 52,944 shares

Expires 2031-12-06

F1 · derivative.exercise_date: These stock options vest 25% on July 19, 2022, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.

SEC source: 0000899243-21-045363 · doc4.xml · nonDerivative · entry 1

Civik Thomas · CIK 0001723092 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Civik Family Trust

Disclosed balance after: 15,700

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.47 to $13.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F2 · ownership.nature: These shares are held directly by the Civik Family Trust, a revocable trust for which the Reporting Person and his spouse are the grantors.

SEC source: 0001140361-21-034643 · form4.xml · derivative · entry 2

FLAVIN JOHN L · CIK 0001126556 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,388 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: These shares of Series B Convertible Preferred Stock converted automatically and for no additional consideration into Common Stock on a 6.359-for-1 basis upon completion of the Issuer's initial public offering (with fractional shares paid out in cash). The shares of Series B Convertible Preferred Stock had no expiration date.

F1 · derivative.exercise_date: These shares of Series B Convertible Preferred Stock converted automatically and for no additional consideration into Common Stock on a 6.359-for-1 basis upon completion of the Issuer's initial public offering (with fractional shares paid out in cash). The shares of Series B Convertible Preferred Stock had no expiration date.

F1 · derivative.expiration_date: These shares of Series B Convertible Preferred Stock converted automatically and for no additional consideration into Common Stock on a 6.359-for-1 basis upon completion of the Issuer's initial public offering (with fractional shares paid out in cash). The shares of Series B Convertible Preferred Stock had no expiration date.

SEC source: 0001140361-21-034643 · form4.xml · nonDerivative · entry 1

FLAVIN JOHN L · CIK 0001126556 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 171,610

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: These shares of Series B Convertible Preferred Stock converted automatically and for no additional consideration into Common Stock on a 6.359-for-1 basis upon completion of the Issuer's initial public offering (with fractional shares paid out in cash). The shares of Series B Convertible Preferred Stock had no expiration date.

F2 · balance_after: Includes 47,593 shares of restricted stock that are subject to vesting in six, substantially-equal quarterly installments beginning October 22, 2021, subject to the reporting person's continued service through the applicable vesting date.

SEC source: 0001578563-21-000038 · primary_doc.xml · derivative · entry 3

Bayer World Investments B.V. · CIK 0001820027 · Former 10% Owner

BAYER AKTIENGESELLSCHAFT · CIK 0001144145 · Former 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 955,507 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date.

F1 · price: Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date.

F1 · derivative.exercise_date: Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date.

F1 · derivative.expiration_date: Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date.

F2 · ownership.direct: The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V.

SEC source: 0001578563-21-000038 · primary_doc.xml · derivative · entry 2

Bayer World Investments B.V. · CIK 0001820027 · Former 10% Owner

BAYER AKTIENGESELLSCHAFT · CIK 0001144145 · Former 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,786,831 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date.

F1 · price: Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date.

F1 · derivative.exercise_date: Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date.

F1 · derivative.expiration_date: Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date.

F2 · ownership.direct: The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V.

SEC source: 0001578563-21-000038 · primary_doc.xml · nonDerivative · entry 1

Bayer World Investments B.V. · CIK 0001820027 · Former 10% Owner

BAYER AKTIENGESELLSCHAFT · CIK 0001144145 · Former 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,742,338

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date.

F2 · ownership.direct: The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V.

SEC source: 0001567619-21-018355 · doc1.xml · derivative · entry 3

Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner

Chen Bihua · CIK 0001599214 · Director · Former 10% Owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · Former 10% Owner

Cormorant Private Healthcare Fund III LP · CIK 0001817320 · Former 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

Underlying: Common Stock · 668,854 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Shares of Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering.

F1 · price: Shares of Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Shares of Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Shares of Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund III, LP ("Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

F5 · ownership.nature: The Series B Convertible Preferred Stock represented, on an as-converted basis, (i) 146,479 shares held by the Master Fund, (ii) 510,503 shares held by Fund III, and (iii) 11,872 shares held by the Account.

SEC source: 0001567619-21-018355 · doc1.xml · nonDerivative · entry 2

Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner

Chen Bihua · CIK 0001599214 · Director · Former 10% Owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · Former 10% Owner

Cormorant Private Healthcare Fund III LP · CIK 0001817320 · Former 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,118,854

F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund III, LP ("Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

F4 · ownership.nature: Shares reported herein as purchased on October 13, 2021 represent 450,000 shares purchased by the Master Fund.

SEC source: 0001567619-21-018355 · doc1.xml · nonDerivative · entry 1

Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner

Chen Bihua · CIK 0001599214 · Director · Former 10% Owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · Former 10% Owner

Cormorant Private Healthcare Fund III LP · CIK 0001817320 · Former 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 668,854

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Shares of Series B Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund III, LP ("Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

F3 · ownership.nature: Represents (i) 146,479 shares held by the Master Fund, (ii) 510,503 shares held by Fund III, and (iii) 11,872 shares held by the Account.

SEC source: 0001140361-21-034645 · form4.xml · derivative · entry 3

Chin Mark · CIK 0001734389 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,433,261 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: These shares of Series B Convertible Preferred Stock converted automatically and for no additional consideration into Common Stock on a 6.359-for-1 basis upon completion of the Issuer's initial public offering (with fractional shares paid out in cash). The shares of Series B Convertible Preferred Stock had no expiration date.

F1 · derivative.exercise_date: These shares of Series B Convertible Preferred Stock converted automatically and for no additional consideration into Common Stock on a 6.359-for-1 basis upon completion of the Issuer's initial public offering (with fractional shares paid out in cash). The shares of Series B Convertible Preferred Stock had no expiration date.

F1 · derivative.expiration_date: These shares of Series B Convertible Preferred Stock converted automatically and for no additional consideration into Common Stock on a 6.359-for-1 basis upon completion of the Issuer's initial public offering (with fractional shares paid out in cash). The shares of Series B Convertible Preferred Stock had no expiration date.

F2 · ownership.direct: These securities are held directly by Arix Bioscience Holdings Limited ("Arix"). The reporting person is one of four members of the Investment Committee of Arix and, in such capacity, may be deemed to share voting and dispositive power over the securities held by Arix. The reporting person disclaims beneficial ownership of such securities except to the extent of his respective pecuniary interests therein.

F2 · ownership.nature: These securities are held directly by Arix Bioscience Holdings Limited ("Arix"). The reporting person is one of four members of the Investment Committee of Arix and, in such capacity, may be deemed to share voting and dispositive power over the securities held by Arix. The reporting person disclaims beneficial ownership of such securities except to the extent of his respective pecuniary interests therein.

SEC source: 0001140361-21-034645 · form4.xml · nonDerivative · entry 2

Chin Mark · CIK 0001734389 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,745,761

F2 · ownership.direct: These securities are held directly by Arix Bioscience Holdings Limited ("Arix"). The reporting person is one of four members of the Investment Committee of Arix and, in such capacity, may be deemed to share voting and dispositive power over the securities held by Arix. The reporting person disclaims beneficial ownership of such securities except to the extent of his respective pecuniary interests therein.

F2 · ownership.nature: These securities are held directly by Arix Bioscience Holdings Limited ("Arix"). The reporting person is one of four members of the Investment Committee of Arix and, in such capacity, may be deemed to share voting and dispositive power over the securities held by Arix. The reporting person disclaims beneficial ownership of such securities except to the extent of his respective pecuniary interests therein.

SEC source: 0001140361-21-034645 · form4.xml · nonDerivative · entry 1

Chin Mark · CIK 0001734389 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,433,261

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: These shares of Series B Convertible Preferred Stock converted automatically and for no additional consideration into Common Stock on a 6.359-for-1 basis upon completion of the Issuer's initial public offering (with fractional shares paid out in cash). The shares of Series B Convertible Preferred Stock had no expiration date.

F2 · ownership.direct: These securities are held directly by Arix Bioscience Holdings Limited ("Arix"). The reporting person is one of four members of the Investment Committee of Arix and, in such capacity, may be deemed to share voting and dispositive power over the securities held by Arix. The reporting person disclaims beneficial ownership of such securities except to the extent of his respective pecuniary interests therein.

F2 · ownership.nature: These securities are held directly by Arix Bioscience Holdings Limited ("Arix"). The reporting person is one of four members of the Investment Committee of Arix and, in such capacity, may be deemed to share voting and dispositive power over the securities held by Arix. The reporting person disclaims beneficial ownership of such securities except to the extent of his respective pecuniary interests therein.

SEC source: 0001140361-21-034426 · form4.xml · derivative · entry 1

FLAVIN JOHN L · CIK 0001126556 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,191

Underlying: Common Stock · 42,191 shares

Expires 2031-10-07

F1 · derivative.exercise_date: These stock options vest as to 1/3 of the shares covered by the option on each annual general meeting of the Issuer's stockholders following the October 7, 2021 grant date, subject to the reporting person's continued service through the applicable vesting date.

SEC source: 0001140361-21-034420 · form4.xml · derivative · entry 1

Herbst Ronald · CIK 0001886107 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,252

Underlying: Common Stock · 28,252 shares

Expires 2031-10-07

F1 · derivative.exercise_date: These stock options vest 25% on the first anniversary of the October 7, 2021 grant date, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.

SEC source: 0001140361-21-034424 · form4.xml · derivative · entry 2

Feingold Jay · CIK 0001885838 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 436,929

Underlying: Common Stock · 436,929 shares

Expires 2031-10-07

F2 · derivative.exercise_date: These stock options vest 25% on the first anniversary of September 13, 2021, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.

SEC source: 0001140361-21-034424 · form4.xml · nonDerivative · entry 1

Feingold Jay · CIK 0001885838 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,750

F1 · shares: Represents shares of restricted stock that vest 25% of the first anniversary of September 13, 2021, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.

SEC source: 0001140361-21-034423 · form4.xml · derivative · entry 1

Chin Mark · CIK 0001734389 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,191

Underlying: Common Stock · 42,191 shares

Expires 2031-10-07

F1 · derivative.exercise_date: These stock options vest as to 1/3 of the shares covered by the option on each annual general meeting of the Issuer's stockholders following the October 7, 2021 grant date, subject to the reporting person's continued service through the applicable vesting date.

SEC source: 0001140361-21-034422 · form4.xml · derivative · entry 1

Lewis-Hall Freda C · CIK 0001437909 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,191

Underlying: Common Stock · 42,191 shares

Expires 2031-10-07

F1 · derivative.exercise_date: These stock options vest as to 1/3 of the shares covered by the option on each annual general meeting of the Issuer's stockholders following the October 7, 2021 grant date, subject to the reporting person's continued service through the applicable vesting date.

SEC source: 0001140361-21-034425 · form4.xml · derivative · entry 1

Cline Darren S · CIK 0001633639 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,191

Underlying: Common Stock · 42,191 shares

Expires 2031-10-07

F1 · derivative.exercise_date: These stock options vest as to 1/3 of the shares covered by the option on each annual general meeting of the Issuer's stockholders following the October 7, 2021 grant date, subject to the reporting person's continued service through the applicable vesting date.

SEC source: 0001140361-21-034427 · form4.xml · derivative · entry 1

Civik Thomas · CIK 0001723092 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,191

Underlying: Common Stock · 42,191 shares

Expires 2031-10-07

F1 · derivative.exercise_date: These stock options vest as to 1/3 of the shares covered by the option on each annual general meeting of the Issuer's stockholders following the October 7, 2021 grant date, subject to the reporting person's continued service through the applicable vesting date.

SEC source: 0001140361-21-034421 · form4.xml · derivative · entry 1

Sullivan Lara · CIK 0001769457 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 962,289

Underlying: Common Stock · 962,289 shares

Expires 2031-10-07

F1 · derivative.exercise_date: Two-thirds of these stock options vest 25% on the first anniversary of the October 7, 2021 grant date, and then in 36 substantially-equal monthly installments thereafter, and one-third of these stock options vest in full on the fourth anniversary of the October 7, 2021 grant date, all subject to the reporting person's continued employment through the applicable vesting date.

SEC source: 0001140361-21-034419 · form4.xml · derivative · entry 1

Shah Ritu · CIK 0001885313 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,344

Underlying: Common Stock · 31,344 shares

Expires 2031-10-07

F1 · derivative.exercise_date: These stock options vest 25% on the first anniversary of the October 7, 2021 grant date, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.